Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
- 8 April 2010
- journal article
- research article
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 26 (6), 1285-1293
- https://doi.org/10.1185/03007991003771338
Abstract
Many children with severe persistent allergic (IgE-mediated) asthma remain inadequately controlled despite treatment with high-dose inhaled corticosteroids (ICS) plus a long-acting β2-agonist (LABA). This pre-specified analysis of a randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of omalizumab in children (6–−1 or equivalent) plus a LABA. Patients received omalizumab (75–375 mg once or twice a month by subcutaneous injection, as determined from dosing tables) or placebo over 52 weeks (24-week fixed-steroid then 28-week adjustable-steroid phases). Out of 246 randomized patients (omalizumab, n = 166; placebo, n = 80), efficacy was analysed in 235 (omalizumab, n = 159; placebo, n = 76). Over the 24-week fixed-steroid phase, omalizumab reduced the rate of clinically significant asthma exacerbations (worsening symptoms requiring doubling of baseline ICS dose and/or systemic steroids) by 34% versus placebo (0.42 vs 0.63, rate ratio 0.662; P = 0.047). Over 52 weeks, the exacerbation rate was reduced by 50% (P < 0.001). Omalizumab had an acceptable safety profile, with no statistically significant (P < 0.05) differences in adverse events observed between omalizumab and placebo. Add-on omalizumab is well-tolerated and reduces exacerbations in children (6–<12 years) with severe persistent allergic asthma, inadequately controlled despite high-dose ICS plus a LABA. It should be noted that the sample size was not based on providing statistical power in the severe subgroup, and no corrections were made for multiple comparisons; however, outcomes consistently favoured omalizumab.Keywords
This publication has 34 references indexed in Scilit:
- Effect of Long-term Corticosteroid Use on Bone Mineral Density in Children: A Prospective Longitudinal Assessment in the Childhood Asthma Management Program (CAMP) StudyPEDIATRICS, 2008
- Asthma cases attributable to atopy: Results from the Third National Health and Nutrition Examination SurveyJournal of Allergy and Clinical Immunology, 2007
- Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxideJournal of Allergy and Clinical Immunology, 2006
- Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthmaAnnals of Allergy, Asthma & Immunology, 2005
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical & Experimental Allergy, 2004
- Effect of long‐acting β2 agonists on exacerbation rates of asthma in childrenPediatric Pulmonology, 2003
- Safety of the Newer Inhaled Corticosteroids in Childhood AsthmaPediatric Drugs, 2003
- Classifying asthma severity in children: Is measuring lung function helpful?Journal of Allergy and Clinical Immunology, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001